Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
公司代碼DYAI
公司名稱Dyadic International Inc
上市日期Nov 05, 2004
CEOEmalfarb (Mark A)
員工數量6
證券類型Ordinary Share
年結日Nov 05
公司地址1044 North U.S. Highway One
城市JUPITER
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編33477
電話15617438333
網址https://dyadic.com/
公司代碼DYAI
上市日期Nov 05, 2004
CEOEmalfarb (Mark A)